Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IKT NASDAQ:IZTC NASDAQ:JNCE NYSE:PLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.60+2.6%$1.76$1.12▼$4.20$119.23M0.92182,998 shs156,902 shsIZTCInvizyne Technologies$12.40$10.02$8.50▼$23.00$77.53MN/A37,647 shs1,129 shsJNCEJounce Therapeutics$1.88$1.89$0.58▼$5.87$98.94M0.752.46 million shs169,314 shsPLXProtalix BioTherapeutics$1.91+5.5%$1.54$0.99▼$3.10$152.29M-0.23829,611 shs1.35 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics0.00%-6.59%-10.86%-19.59%+32.20%IZTCInvizyne Technologies0.00%+3.68%+24.12%-3.20%+1,239,999,900.00%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%0.00%PLXProtalix BioTherapeutics0.00%+17.53%+22.30%+26.57%+72.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.60+2.6%$1.76$1.12▼$4.20$119.23M0.92182,998 shs156,902 shsIZTCInvizyne Technologies$12.40$10.02$8.50▼$23.00$77.53MN/A37,647 shs1,129 shsJNCEJounce Therapeutics$1.88$1.89$0.58▼$5.87$98.94M0.752.46 million shs169,314 shsPLXProtalix BioTherapeutics$1.91+5.5%$1.54$0.99▼$3.10$152.29M-0.23829,611 shs1.35 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics0.00%-6.59%-10.86%-19.59%+32.20%IZTCInvizyne Technologies0.00%+3.68%+24.12%-3.20%+1,239,999,900.00%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%0.00%PLXProtalix BioTherapeutics0.00%+17.53%+22.30%+26.57%+72.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics 2.50Moderate Buy$6.50306.25% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/AJNCEJounce Therapeutics 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$15.00685.34% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AJNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53PLXProtalix BioTherapeutics$61.95M2.46$0.11 per share17.80$0.47 per share4.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AIZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AJNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/APLXProtalix BioTherapeutics$8.31M$0.07N/A6.16N/A-21.03%-30.89%-11.74%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A0.850.85IZTCInvizyne TechnologiesN/AN/AN/AJNCEJounce TherapeuticsN/A8.378.37PLXProtalix BioTherapeuticsN/A1.981.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%IZTCInvizyne TechnologiesN/AJNCEJounce Therapeutics80.66%PLXProtalix BioTherapeutics16.53%Insider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics7.30%IZTCInvizyne TechnologiesN/AJNCEJounce Therapeutics6.92%PLXProtalix BioTherapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics674.52 million66.18 millionNot OptionableIZTCInvizyne Technologies296.25 millionN/AN/AJNCEJounce Therapeutics13752.63 million48.99 millionOptionablePLXProtalix BioTherapeutics20079.73 million69.00 millionOptionableJNCE, PLX, IKT, and IZTC HeadlinesRecent News About These CompaniesProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics to Present at Investor Summit VirtualSeptember 11, 2025 | finanznachrichten.deProtalix BioTherapeutics to Present at Investor Summit VirtualSeptember 11, 2025 | accessnewswire.comAOMERS ADMINISTRATION Corp Buys New Stake in Protalix BioTherapeutics, Inc. $PLXSeptember 5, 2025 | marketbeat.comProtalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio RampAugust 25, 2025 | seekingalpha.comProtalix Amends Market Offering Agreement with H.C. WainwrightAugust 22, 2025 | msn.comHC Wainwright Has Pessimistic View of PLX FY2025 EarningsAugust 22, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of PLX Q3 EarningsAugust 21, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Acquires New Stake in Protalix BioTherapeutics, Inc. (NYSE:PLX)August 18, 2025 | marketbeat.comPLX: New CFO to Take the ReinsAugust 16, 2025 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | insidermonkey.comProtalix BioTherapeutics Reports Strong Q2 2025 ResultsAugust 15, 2025 | msn.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business ResultsAugust 14, 2025 | finanznachrichten.deProtalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comProtalix BioTherapeutics lifts revenue on strong Elfabrio demandAugust 14, 2025 | proactiveinvestors.comProtalix BioTherapeutics Reports Second Quarter 2025 Financial and Business ResultsAugust 14, 2025 | prnewswire.comProtalix BioTherapeutics, Inc. (NYSE:PLX) Director Aharon Schwartz Buys 129,000 SharesAugust 13, 2025 | insidertrades.comProtalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025August 7, 2025 | prnewswire.comProtalix Lawsuit Dismissed After Bylaws AmendmentAugust 1, 2025 | tipranks.comProtalix BioTherapeutics Names Gilad Mamlok Chief Financial OfficerJuly 21, 2025 | marketwatch.comProtalix BioTherapeutics Names SVP and CFOJuly 21, 2025 | contractpharma.comCProtalix Biotherapeutics Inc.: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial OfficerJuly 21, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJNCE, PLX, IKT, and IZTC Company DescriptionsInhibikase Therapeutics NYSE:IKT$1.60 +0.04 (+2.56%) Closing price 04:00 PM EasternExtended Trading$1.60 +0.00 (+0.31%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Invizyne Technologies NASDAQ:IZTC$12.40 0.00 (0.00%) As of 09/12/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Jounce Therapeutics NASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.Protalix BioTherapeutics NYSE:PLX$1.91 +0.10 (+5.52%) Closing price 04:00 PM EasternExtended Trading$1.91 0.00 (0.00%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
